Alvotech (ALVOW) 股票分析

公司概述

Alvotech is a biopharmaceutical entity dedicated to the development and manufacturing of biosimilar medicines for patients globally across therapeutic areas including autoimmune conditions, eye disorders, bone disorders, and cancer. The company specifically provides AVT02, which is a high concentration, low-volume adalimumab formula, serving as a key product in its portfolio. While specific sector and industry classifications are not disclosed in the provided data, the company operates with a significant workforce of 1,279 employees, indicating a substantial operational footprint. The company reports a trailing twelve-month revenue of $588.90 million, yet the market capitalization is not listed in the available facts, which limits the ability to quantify its total enterprise value directly. This revenue figure, combined with the employee base, suggests a mature scale operation focused on specialized biosimilar delivery rather than early-stage clinical trial expansion.

财务健康

The company generated $588.90 million in revenue over the trailing twelve months, resulting in a net income of $27.92 million and an EBITDA of $103.98 million. The gap between the $588.90 million revenue and the $27.92 million net income reveals a cost structure where non-operating expenses, interest, or taxes significantly impact the bottom line before arriving at net profit. Alvotech maintains a free cash flow of $24.60 million, which provides a measure of financial flexibility for funding operations or potential strategic initiatives without relying solely on external financing. The gross margin stands at 60.0%, indicating a typical high-cost structure common in biosimilar manufacturing where production costs are a significant portion of revenue. The operating margin is 33.8%, reflecting efficient management of operating expenses relative to sales, while the profit margin sits at 4.7%, showing the final profitability after all costs. On the balance sheet, the company holds $172.36 million in cash against $1.45 billion in debt, creating a distinct leverage position. The debt-to-equity ratio is not provided, but the presence of $1.45 billion in debt relative to $172.36 million in cash suggests a highly leveraged capital structure. The current ratio of 1.89 indicates that the company possesses $1.89 in current assets for every $1 of current liabilities, signaling strong short-term liquidity. Return on Equity and Return on Assets are not available, but the available Return on Assets is 3.8%, which offers insight into asset utilization efficiency.

估值评估

The trailing P/E ratio and forward P/E ratio are not available in the provided data, preventing a direct comparison of current earnings expectations versus historical performance. The price-to-book ratio is reported at -0.27, which indicates a market valuation below the book value of equity, a metric often seen in capital-intensive or loss-making entities, though this company reports positive net income. The price-to-sales ratio and EV/EBITDA are also not listed, meaning alternative valuation multiples cannot be calculated from the current facts. The stock's 52-week high is $0.29 and the 52-week low is $0.25, defining the recent trading range for this equity. Without a specific current share price in the facts, the exact percentage deviation from the 52-week high or low cannot be calculated, but the trading range is narrow, suggesting low volatility in recent periods. The beta value is 0.25, which implies that the stock's price volatility is significantly lower than the broader market, moving less than one-quarter as much as the general index in response to market fluctuations.

Growth & Income

The revenue growth year-over-year is 10.1%, demonstrating double-digit expansion in sales, while the earnings growth year-over-year is not available to compare against revenue expansion. Since earnings growth data is missing, it is impossible to determine if net income is growing faster or slower than the 10.1% revenue rate, but the positive net income confirms profitability. The company does not pay dividends, as indicated by the absence of a dividend yield and payout ratio in the available facts, meaning it retains all earnings for reinvestment. This reinvestment strategy aligns with the company's focus on manufacturing biosimilars and expanding its presence in autoimmune and oncology markets. The overall growth profile is characterized by steady double-digit revenue growth without the pressure of dividend payouts, while the income profile relies entirely on retained earnings to support operations and debt obligations.